BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 21446043)

  • 1. Treatment-related mortality in children with acute lymphoblastic leukemia in Central America.
    Gupta S; Antillon FA; Bonilla M; Fu L; Howard SC; Ribeiro RC; Sung L
    Cancer; 2011 Oct; 117(20):4788-95. PubMed ID: 21446043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment-related mortality in children with acute myeloid leukaemia in Central America: incidence, timing and predictors.
    Gupta S; Bonilla M; Valverde P; Fu L; Howard SC; Ribeiro RC; Sung L
    Eur J Cancer; 2012 Jun; 48(9):1363-9. PubMed ID: 22082459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.
    Nachman JB; Sather HN; Sensel MG; Trigg ME; Cherlow JM; Lukens JN; Wolff L; Uckun FM; Gaynon PS
    N Engl J Med; 1998 Jun; 338(23):1663-71. PubMed ID: 9614257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation of an intensive risk-stratified treatment protocol for children and adolescents with acute lymphoblastic leukemia in Lebanon.
    Muwakkit S; Al-Aridi C; Samra A; Saab R; Mahfouz RA; Farra C; Jeha S; Abboud MR
    Am J Hematol; 2012 Jul; 87(7):678-83. PubMed ID: 22565284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan.
    Matsuzaki A; Ishii E; Okamura J; Eguchi H; Yoshida N; Yanai F; Inoue T; Miyake K; Ishihara T; Tsuboi C
    Med Pediatr Oncol; 1996 Jan; 26(1):10-9. PubMed ID: 7494507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
    Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
    Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of modified St Jude total therapy 13A for childhood acute lymphoblastic leukemia in the southeast region of Turkey.
    Koc A; Aycicek A; Ozdemir ZC; Soker M; Varma M
    J Pediatr Hematol Oncol; 2013 Jan; 35(1):36-41. PubMed ID: 23138117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia.
    Pui CH; Boyett JM; Hughes WT; Rivera GK; Hancock ML; Sandlund JT; Synold T; Relling MV; Ribeiro RC; Crist WM; Evans WE
    N Engl J Med; 1997 Jun; 336(25):1781-7. PubMed ID: 9187068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study.
    Oudot C; Auclerc MF; Levy V; Porcher R; Piguet C; Perel Y; Gandemer V; Debre M; Vermylen C; Pautard B; Berger C; Schmitt C; Leblanc T; Cayuela JM; Socie G; Michel G; Leverger G; Baruchel A
    J Clin Oncol; 2008 Mar; 26(9):1496-503. PubMed ID: 18349402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89). Spanish Society of Hematology.
    Ribera JM; Ortega JJ; Oriol A; Fontanillas M; Hernández-Rivas JM; Brunet S; García-Conde J; Maldonado J; Zuazu J; Gardella S; Besalduch J; León P; Macià J; Domingo-Albós A; Feliu E; San Miguel JF
    Haematologica; 1998 Mar; 83(3):222-30. PubMed ID: 9573676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dimensions of child sexual abuse before age 15 in three Central American countries: Honduras, El Salvador, and Guatemala.
    Speizer IS; Goodwin M; Whittle L; Clyde M; Rogers J
    Child Abuse Negl; 2008 Apr; 32(4):455-62. PubMed ID: 18455794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children.
    Koren G; Ferrazini G; Sulh H; Langevin AM; Kapelushnik J; Klein J; Giesbrecht E; Soldin S; Greenberg M
    N Engl J Med; 1990 Jul; 323(1):17-21. PubMed ID: 2355954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proportion of long-term event-free survivors and lifetime of adult patients not cured after a standard acute lymphoblastic leukemia therapeutic program: adult acute lymphoblastic leukemia-94 trial.
    Le QH; Thomas X; Ecochard R; Iwaz J; Lhéritier V; Michallet M; Fiere D
    Cancer; 2007 May; 109(10):2058-67. PubMed ID: 17407135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Ontario children with acute lymphoblastic leukemia by the Dana-Farber Cancer Institute protocols.
    Desai SJ; Barr RD; Andrew M; deVeber LL; Pai MK
    CMAJ; 1989 Oct; 141(7):693-7. PubMed ID: 2790605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
    van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
    Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia.
    Evans WE; Relling MV; Rodman JH; Crom WR; Boyett JM; Pui CH
    N Engl J Med; 1998 Feb; 338(8):499-505. PubMed ID: 9468466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL.
    Ortega JJ; Ribera JM; Oriol A; Bastida P; González ME; Calvo C; Egurbide I; Hernández Rivas JM; Rivas C; Alcalá A; Besalduch J; Maciá J; Gardella S; Carnero M; Lite JM; Casanova F; Martinez M; Fontanillas M; Feliu E; San Miguel JF;
    Haematologica; 2001 Jun; 86(6):586-95. PubMed ID: 11418367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia.
    Mahmoud HH; Rivera GK; Hancock ML; Krance RA; Kun LE; Behm FG; Ribeiro RC; Sandlund JT; Crist WM; Pui CH
    N Engl J Med; 1993 Jul; 329(5):314-9. PubMed ID: 8321259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia.
    Pui CH; Cheng C; Leung W; Rai SN; Rivera GK; Sandlund JT; Ribeiro RC; Relling MV; Kun LE; Evans WE; Hudson MM
    N Engl J Med; 2003 Aug; 349(7):640-9. PubMed ID: 12917300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Childhood acute lymphoblastic leukemia in Norway 1992-2000].
    Kolmannskog S; Flaegstad T; Helgestad J; Hellebostad M; Zeller B; Glomstein A
    Tidsskr Nor Laegeforen; 2007 May; 127(11):1493-5. PubMed ID: 17551551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.